Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
0.7100
+0.0500 (7.58%)
Lineage Cell Therapeutics Inc is a biotechnology company focused on developing innovative cell-based therapies for the treatment of a range of diseases, particularly those affecting the eye and nervous system
The company is dedicated to utilizing its proprietary technology and expertise in cell therapy to create regenerative medicine solutions that can improve patient outcomes. By leveraging advancements in stem cell research and regenerative medicine, Lineage aims to address unmet medical needs through its clinical programs and preclinical research initiatives, contributing to the evolution of therapeutic strategies in regenerative healthcare.
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Lineage Cell Therapeutics Inc (NYSELCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and license agreement with Eterna Therapeutics Inc (NASDAQ:
Lineage Cell Therapeutics Inc (NYSELCTX) and Cancer Research UK revealed primary and secondary endpoint results from the recently completed clinical study of VAC2 in advanced non-small
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQIDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
